Development and validation of the candidate European Pharmacopoeia (Ph. Eur.) standard method for quantification of the major birch pollen allergen, Bet v 1

Hindley James; Smith Bryan; Oliver Maria; Chapman Martin

首页> 外文期刊>Clinical and experimental allergy : >Development and validation of the candidate European Pharmacopoeia (Ph. Eur.) standard method for quantification of the major birch pollen allergen, Bet v 1

【24h】

Development and validation of the candidate European Pharmacopoeia (Ph. Eur.) standard method for quantification of the major birch pollen allergen, Bet v 1

机译：候选欧洲药典（pH。EUR。）定量大桦树花粉过敏原的标准方法的发展与验证，BET v 1

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical and experimental allergy :》 |2017年第12期|共2页
作者
Hindley James; Smith Bryan; Oliver Maria; Chapman Martin;
展开▼
作者单位

Indoor Biotechnol Cardiff S Glam Wales;

Indoor Biotechnol Charlottesville VA USA;

Indoor Biotechnol Cardiff S Glam Wales;

Indoor Biotechnol Charlottesville VA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Development and validation of the candidate European Pharmacopoeia (Ph. Eur.) standard method for quantification of the major birch pollen allergen, Bet v 1 [J] . Hindley James, Smith Bryan, Oliver Maria, Clinical and experimental allergy : . 2017,第12期

机译：候选欧洲药典（pH。EUR。）定量大桦树花粉过敏原的标准方法的发展与验证，BET v 1
2. Standardization of allergen products: 3. Validation of candidate European Pharmacopoeia standard methods for quantification of major birch allergen Bet v 1 [J] . Kaul S., Zimmer J., Dehus O., Allergy . 2016,第10期

机译：变应原产品的标准化：3.验证主要桦木变应原Bet v 1定量的候选欧洲药典标准方法
3. Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement [J] . S. Vieths, D. Barber, M. Chapman, Pharmeuropa bio & scientific notes. . 2012,第Null期

机译：重组主要变应原Bet v 1和Phl p 5a的建立。参考标准和ELISA方法的验证
4. Antibody Responses to Minor Allergen Bet v 2 During Allergen-Specific Immunotherapy in Birch Pollen-Allergic Patients [C] . J.N. Larsen, U. Bodtger, L.K. Poulsen, Collegium Internationale Allergologicum . 2007

机译：在桦木花粉过敏患者中过敏原特异性免疫疗法期间对次要过敏原BβV2的抗体反应
5. Production of recombinant allergen birch pollen Betv1a modified with hydrophobic moieties in the host Escherichia coli. [D] . Bensoussan, Michael. 2002

机译：在宿主大肠杆菌中用疏水部分修饰的重组变应原桦树花粉Betv1a的生产。
6. The Major Birch Pollen Allergen Bet v 1 Induces Different Responses in Dendritic Cells of Birch Pollen Allergic and Healthy Individuals [O] . Ursula Smole, Christian Radauer, Nina Lengger, 2015

机译：主要桦木花粉过敏原Bet v 1在桦木花粉过敏和健康个体的树突状细胞中诱导不同的反应
7. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. [O] . Vrtala, S, Hirtenlehner, K, Vangelista, L, 1997

机译：将主要的桦树花粉变应原Bet v 1转换为两个包含非过敏性T细胞表位的片段：新型免疫疗法的候选形式。

Development and validation of the candidate European Pharmacopoeia (Ph. Eur.) standard method for quantification of the major birch pollen allergen, Bet v 1

著录项

相似文献

相关主题

期刊订阅